Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11)

Journal of Controlled Release

Volumn 115, Issue 2, 2006, Pages 134-139

  Takagi, Akira ^a   Yamashita, Noboru ^a   Yoshioka, Tatsunobu ^a   Takaishi, Yuuki ^a   Nakanishi, Kiyo ^a   Takemura, Shigeo ^a   Maeda, Atsushi ^a   Saito, Katsumi ^a   Takakura, Yoshinobu ^b   Hashida, Mitsuru ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Hyaluronic acid; Ionic interaction; Protamine; rhIL11; Sustained release

Indexed keywords

HYALURONIC ACID; IONIC INTERACTION; PROTAMINE; RHIL11; SUSTAINED RELEASE;

AMINES; BIODEGRADATION; BIOMEDICAL ENGINEERING; CARBOXYLIC ACIDS; DRUG THERAPY; PROTEINS;

POLYSACCHARIDES;

HYALURONIC ACID; PROTAMINE; RECOMBINANT INTERLEUKIN 11;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; COMPARATIVE STUDY; COMPRESSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FREEZE DRYING; MALE; NONHUMAN; OSMOTIC PUMP; POWDER; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; THROMBOCYTE COUNT;

ANIMALS; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GEL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYALURONIC ACID; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-11; MALE; PLATELET COUNT; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 33749577303     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.07.016     Document Type: Article

References (31)

1. Bucht A., Larsson P., Weisbrot L., Thorne C., Pisa P., Smedegard G., Keystone E.C., and Gronberg A. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin. Exp. Immunol. 103 (1996) 357-367
2. Kaushansky K. Thrombopoietin: from theory to reality. Int. J. Hematol. 76 (2002) 343-345
3. Veronese F.M., and Harris J.M. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. 54 (2002) 453-456
4. Du X., and Williams D.A. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 89 (1997) 3897-3908
5. Leary A.G., Zeng H.Q., Clark S.C., and Ogawa M. Growth factor requirements for survival in G0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4013-4017
6. Leonard J.P., Quinto C.M., Kozitza M.K., Neben T.Y., and Goldman S.J. Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 83 (1994) 1499-1506
7. Neben T.Y., Loebelenz J., Hayes L., McCarthy K., Stoudemire J., Schaub R., and Goldman S.J. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 81 (1993) 901-908
8. Tepler I., Elias L., Smith II J.W., Hussein M., Rosen G., Chang A.Y., Moore J.O., Gordon M.S., Kuca B., Beach K.J., Loewy J.W., Garnick M.B., and Kaye J.A. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87 (1996) 3607-3614
9. Takagi A., Masuda H., Takakura Y., and Hashida M. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther. 275 (1995) 537-543
10. Uchida T., Aoyama K., Mori K., Usui T., Watanabe T., Takariki Y., Asahara N., Hirose M., Kimura T., Tateishi M., and Higuchi S. Pharmacokinetics of [125I]-recombinant human interleukin-11: 1. Absorption, distribution and excretion after subcutaneous administration to male rats. Eur. J. Drug Metab. Pharmacokinet. 23 (1998) 403-410
11. Yonemura Y., Kawakita M., Masuda T., Fujimoto K., and Takatsuki K. Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin-6. Br. J. Haematol. 84 (1993) 16-23
12. Gordon M.S. Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy. Cancer Chemother. Pharmacol. 38 (1996) S96-S98
13. Teramura M., Kobayashi S., Yoshinaga K., Iwabe K., and Mizoguchi H. Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother. Pharmacol. 38 (1996) S99-S102
14. Gordon M.S., McCaskill-Stevens W.J., Battiato L.A., Loewy J., Loesch D., Breeden E., Hoffman R., Beach K.J., Kuca B., Kaye J., and Sledge Jr. G.W. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87 (1996) 3615-3624
15. Johnson O.L., Jaworowicz W., Cleland J.L., Bailey L., Charnis M., Duenas E., Wu C., Shepard D., Magil S., Last T., Jones A.J., and Putney S.D. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14 (1997) 730-735
16. Ye Q., Asherman J., Stevenson M., Brownson E., and Katre N.V. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Release 64 (2000) 155-166
17. Hora M.S., Rana R.K., Nunberg J.H., Tice T.R., Gilley R.M., and Hudson M.E. Controlled release of interleukin-2 from biodegradable microspheres. Bio/Technology 8 (1990) 755-758
18. Sah H. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release 58 (1999) 143-151
19. Adams M.E., Lussier A.J., and Peyron J.G. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Safety 23 (2000) 115-130
20. Debbasch C., De La Salle S.B., Brignole F., Rat P., Warnet J.M., and Baudouin C. Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3409-3415
21. Hahn S.K., Jelacic S., Maier R.V., Stayton P.S., and Hoffman A.S. Anti inflammatory drug delivery from hyaluronic acid hydrogels. J. Biomater. Sci., Polym. Ed. 15 (2004) 1111-1119
22. S. Kitano, K. Kitazato, Long-acting physiologically active peptide preparation, Japanese Patent Application JP02000213, Jan. 5, 1990.
23. Y. Igari, M. Yamada, Y. Ogawa, Water-soluble composition, Japanese Patent Application JP05186362, July 27, 1993.
24. Igari Y., Ishiguro S., Yamada M., Ogawa Y., and Toguchi H. Sustained release preparation of erythropoietin using sodium hyaluronate. Drug Deliv. Syst. 8 (1993) 237-241
25. Yokota H., Kishimoto M., Saito H., Sakai T., Yokota S., and Kojima S. Quantitative in vitro bioassay for recombinant human interleukin-11. J. AOAC Int. 83 (2000) 1053-1057
26. Leonard P., Neben T.Y., Kozitza M.K., Quinto C.M., and Goldman S.J. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity. Exp. Hematol. 24 (1996) 270-276
27. Paul S.R., Bennett F., Calvetti J.A., Kelleher K., Wood C.R., O'Hara Jr. R.M., Leary A.C., Sibley B., Clark S.C., and Williams D.A. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 7512-7516
28. Yang B., Zhang L., and Turley E.A. Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J. Biol. Chem. 268 (1993) 8617-8623
29. Yang B., Yang B.L., Savani R.C., and Turley E.A. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J. 13 (1994) 286-296
30. Segura T., Anderson B.C., Chung P.H., Webber R.E., Shull K.R., and Shea L.D. Crosslinked hyaluronic acid hydrogels: a strategy to functionalize and pattern. Biomaterials 26 (2005) 359-371
31. Xin X., Borzacchiello A., Netti P.A., Ambrosio L., and Nicolais L. Hyaluronic-acid-based semi-interpenetrating materials. J. Biomater. Sci., Polym. Ed. 15 (2004) 1223-1236